Company intelligence / Profile preview

Chongqing Daxin

Chongqing, Chongqing, China

Ownership: Private
Employees: ~710
Development stage: Other

Overview

Chongqing Daxin is the world’s largest producer of Lovastatin, with numerous products approved by US FDA (including Lovastatin, Amikacin, hydroxyethyl starch, and Mycophenolic Acid). The company operates at commercial manufacturing scale and is recognized as a key supplier of APIs and finished dosages globally, with highly certified facilities and robust GMP compliance

Therapeutic areas: ImmunologyInfectious DiseasesHematologyCardiovascularOncology
Modalities: Small moleculeBiologicPeptidesAntibioticsPlasma volume expander
Industry: Contract Manufacturing Organization

Partnerships

PKU Healthcare Industry Group (parent/strategic)Peking University (support/institutional synergy)

Beyond the preview

Go deeper on Chongqing Daxin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chongqing Daxin.

Explore the full profile